Type 1 interferon-β (T1IFN-β) is an innate cytokine and the first-choice therapy for multiple sclerosis (MS). It is still unclear how T1IFN-β, whose main function is to promote innate immunity during infections, plays a beneficial role in autoimmune disease. Here we show that T1IFN-β promoted the expansion and function of invariant natural killer (iNKT) cells, an innate T-cell subset with strong immune regulatory properties that is able to prevent autoimmune disease in pre-clinical models of MS and type 1 diabetes. Specifically, we observed that T1IFN-β treatment significantly increased the percentages of Vα24+ NKT cells in peripheral blood mononuclear cells of MS patients. Furthermore, iNKT cells of T1IFN-β-treated individuals showed a dramatically improved secretion of cytokines (interleukins 4 and 5 and interferon-γ) in response to antigenic stimulation compared to iNKT cells isolated from the same patients before T1IFN-β treatment. The effect of T1IFN-β on iNKT cells was mediated through the modulation of myeloid dendritic cells (DCs). In fact, DCs modulated in vivo or in vitro by T1IFN-β were more efficient antigen-presenting cells for iNKT cells. Such a modulatory effect of T1IFN-β was associated with up-regulation on DCs of key costimulatory molecules for iNKT (i.e. CD80, CD40 and CD1d). Our data identified the iNKT cell/DC pathway as a new target for the immune regulatory effect of T1IFNs in autoimmune diseases and provide a possible mechanism to explain the clinical efficacy of T1IFN-β in MS.
- CD1d-restricted natural killer T cells
- Dendritic cells
- Human studies
ASJC Scopus subject areas